Cure8 research brief
Patients with PsA and clinicians choosing long‑term biologic therapy may care about both durability of PsA control and safety signals for related inflammatory conditions like IBD and uveitis. This analysis reports sustained efficacy to 3 years and low rates of IBD/uveitis events in the study population.
Patients with psoriatic arthritis, clinicians treating PsA, researchers in biologic therapies and safety, patients on or considering biologics.
Bimekizumab, an investigational biologic studied in phase 3 PsA trials (BE OPTIMAL, BE COMPLETE) and their open-label extension (BE VITAL), showed sustained benefit across multiple psoriatic arthritis domains to 3 years.
The pooled post hoc analysis reports long-term control of joint, skin, enthesitis, and dactylitis measures, with low rates of inflammatory bowel disease (IBD) and uveitis events and persistent improvement in inflammatory cardiovascular risk markers.
The analysis pooled biologic‑naïve patients and those with prior TNF inhibitor failure who received subcutaneous bimekizumab 160 mg every 4 weeks. Results are from a post hoc pooled analysis and summarized here from the article abstract rather than a full independent review of individual study data.
Key takeaways are about durability of PsA benefit and event rates for IBD and uveitis reported as rare in this cohort; the report does not present IBD-focused efficacy data and does not claim prevention or treatment effects for IBD.
Findings are from a pooled post hoc analysis and open‑label extension; post hoc and open‑label data have limitations compared with prespecified randomized comparisons. The article abstract summarizes results but does not replace review of full trial reports or regulatory safety assessments.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Longer-term data help patients and clinicians understand whether an initial response to a new biologic (mirikizumab) is likely to last and whether safety findings remain acceptable over two years.
The study suggests starting anti-TNF therapy with an immunomodulator at diagnosis may reduce surgery, hospital stays, and progression to complicated Crohn’s over 5 years — outcomes that matter to patients and clinicians...
Perianal fistulas are a significant complication of Crohn’s disease that can be hard to treat. A phase 3 trial reported that guselkumab improved combined fistula remission versus placebo, which could represent a new...
